These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24390519)

  • 21. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine.
    Benlidayi IC; Ortac EA; Kozanoglu E
    Acta Clin Belg; 2015 Apr; 70(2):130-2. PubMed ID: 25338093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis.
    Li LJ; Zhang J; Gao P; Lv F; Song YW; Chang XY; Zhao DC; Wang O; Jiang Y; Xing XP; Xia WB; Li M
    Clin Rheumatol; 2018 Nov; 37(11):3141-3150. PubMed ID: 29946989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
    Papadaki HA; Tsatsanis C; Christoforidou A; Malliaraki N; Psyllaki M; Pontikoglou C; Miliaki M; Margioris AN; Eliopoulos GD
    J Bone Miner Metab; 2004; 22(6):577-87. PubMed ID: 15490268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Eastell R; Chen P; Saag KG; Burshell AL; Wong M; Warner MR; Krege JH
    Bone; 2010 Apr; 46(4):929-34. PubMed ID: 20060078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of alendronate on bone density in men with primary and secondary osteoporosis.
    Ho YV; Frauman AG; Thomson W; Seeman E
    Osteoporos Int; 2000; 11(2):98-101. PubMed ID: 10793867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
    J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
    Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
    Doria C; Mosele GR; Solla F; Maestretti G; Balsano M; Scarpa RM
    Minerva Urol Nefrol; 2017 Jun; 69(3):271-277. PubMed ID: 27813398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
    Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
    J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts.
    Shu G; Yamamoto K; Nagashima M
    Mod Rheumatol; 2006; 16(6):343-9. PubMed ID: 17164994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in blood and urinary cadmium levels and bone mineral density according to osteoporosis medication in individuals with an increased cadmium body burden.
    Eom SY; Yim DH; Hong SM; Kim YD; Kim H; Choi BS; Park JD; Park CH; Kim GB; Yu SD
    Hum Exp Toxicol; 2018 Apr; 37(4):350-357. PubMed ID: 28441892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study.
    Huang WH; Lee SY; Weng CH; Lai PC
    PLoS One; 2012; 7(11):e48481. PubMed ID: 23185261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy.
    Apkon S; Coll J
    Am J Phys Med Rehabil; 2008 Feb; 87(2):139-43. PubMed ID: 17912140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.